Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.

Isaline Coquet, Juliette Pavie, Pierre Palmer, François Barbier, Stéphane Legriel, Julien Mayaux, Jean Michel Molina, Benoît Schlemmer, Elie Azoulay
Author Information
  1. Isaline Coquet: Service de Réanimation Médicale, AP-HP, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, Université Paris-7 Paris-Diderot, UFR de Médecine, 75010 Paris, France. i.coquet@aol.com

Abstract

INTRODUCTION: The widespread use of highly active antiretroviral therapy (ART) has reduced HIV-related life-threatening infectious complications. Our objective was to assess whether highly active ART was associated with improved survival in critically ill HIV-infected patients.
METHODS: A retrospective study from 1996 to 2005 was performed in a medical intensive care unit (ICU) in a university hospital specialized in the management of immunocompromised patients. A total of 284 critically ill HIV-infected patients were included. Differences were sought across four time periods. Risk factors for death were identified by multivariable logistic regression.
RESULTS: Among the 233 (82%) patients with known HIV infection before ICU admission, 64% were on highly active ART. Annual admissions increased over time, with no differences in reasons for admission: proportions of patients with newly diagnosed HIV, previous opportunistic infection, CD4 counts, viral load, or acute disease severity. ICU and 90-day mortality rates decreased steadily: 25% and 37.5% in 1996 to 1997, 17.1% and 17.1% in 1998 to 2000, 13.2% and 13.2% in 2001 to 2003, and 8.6% in 2004 to 2005. Five factors were independently associated with increased ICU mortality: delayed ICU admission (odds ratio (OR), 3.04; 95% confidence interval (CI), 1.29 to 7.17), acute renal failure (OR, 4.21; 95% CI, 1.63 to 10.92), hepatic cirrhosis (OR, 3.78; 95% CI, 1.21 to 11.84), ICU admission for coma (OR, 2.73; 95% CI, 1.16 to 6.46), and severe sepsis (OR, 3.67; 95% CI, 1.53 to 8.80). Admission to the ICU in the most recent period was independently associated with increased survival: admission from 2001 to 2003 (OR, 0.28; 95% CI, 0.08 to 0.99), and between 2004 and 2005 (OR, 0.13; 95% CI, 0.03 to 0.53).
CONCLUSIONS: ICU survival increased significantly in the highly active ART era, although disease severity remained unchanged. Co-morbidities and organ dysfunctions, but not HIV-related variables, were associated with death. Earlier ICU admission from the hospital ward might improve survival.

References

Am Heart J. 2006 Jun;151(6):1147-55 [PMID: 16781213]
Eur Respir J. 2006 Jun;27(6):1210-6 [PMID: 16510452]
Am J Respir Crit Care Med. 2002 Aug 1;166(3):262-7 [PMID: 12153955]
Crit Care Med. 2006 Jan;34(1):42-9 [PMID: 16374154]
AIDS. 2004 Jul 2;18(10):1429-33 [PMID: 15199319]
N Engl J Med. 2006 Jul 13;355(2):173-81 [PMID: 16837681]
Crit Care Med. 2005 Nov;33(11):2488-93 [PMID: 16276171]
Crit Care Med. 2007 Mar;35(3):808-14 [PMID: 17235261]
Arch Intern Med. 2000 Feb 28;160(4):541-7 [PMID: 10695695]
Intensive Care Med. 2008 Jul;34(7):1177-87 [PMID: 18427781]
Crit Care Med. 2001 Nov;29(11):2132-6 [PMID: 11700409]
Chest. 2004 May;125(5):1800-4 [PMID: 15136393]
Chest. 2003 Aug;124(2):459-67 [PMID: 12907529]
Chest. 2000 Jul;118(1):138-45 [PMID: 10893371]
J Hepatol. 2005 Jun;42(6):799-805 [PMID: 15973779]
Crit Care Med. 2003 Jun;31(6):1715-21 [PMID: 12794410]
Intensive Care Med. 2004 May;30(5):859-66 [PMID: 14767592]
Clin Infect Dis. 2003 Apr 15;36(8):1030-8 [PMID: 12684916]
Curr Infect Dis Rep. 2008 Mar;10(1):74-81 [PMID: 18377819]
Curr Opin Oncol. 2009 Jul;21(4):318-26 [PMID: 19436200]
Crit Care Med. 2008 Jan;36(1):100-7 [PMID: 18090351]
Am J Respir Crit Care Med. 1999 Aug;160(2):493-9 [PMID: 10430719]
N Engl J Med. 1998 Mar 26;338(13):853-60 [PMID: 9516219]
N Engl J Med. 2006 Nov 30;355(22):2283-96 [PMID: 17135583]
Thorax. 2007 Nov;62(11):964-8 [PMID: 17517829]
Crit Care Med. 2002 Oct;30(10):2260-70 [PMID: 12394954]
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):194-200 [PMID: 16394852]
Crit Care Med. 2006 Sep;34(9 Suppl):S245-50 [PMID: 16917430]
Chest. 2006 Nov;130(5):1579-95 [PMID: 17099041]
J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 [PMID: 16878047]
HIV Med. 2006 Apr;7(3):193-6 [PMID: 16494634]

MeSH Term

Adult
Antiretroviral Therapy, Highly Active
Cohort Studies
Comorbidity
Critical Illness
Female
HIV Seropositivity
Hospitals, University
Humans
Intensive Care Units
Male
Middle Aged
Odds Ratio
Paris
Regression Analysis
Retrospective Studies
Risk Factors
Survival Analysis
Treatment Outcome

Word Cloud

Similar Articles

Cited By